Media Coverage

This week, a widely shared tweet attempted to cast doubt around COVID-19 vaccines that must be stored at ultracold temperatures. “Any vaccine that needs to be shipped and stored at -80 degrees isn’t a vaccine. It’s a transfection agent, kept alive so it can infect your cells and transfer genetic material. Don’t let them fool you. This is genetic manipulation of humans on a massive scale. Shut it down,” the tweet falsely stated. Two of the leading vaccine candidates are created with messenger RNA, known also as mRNA.

With at least two COVID-19 vaccines expected to receive federal approval in the U.S. within a matter of weeks, hopes for beating the coronavirus are looking up. Yet for millions of workers and businesses, the emerging immunizations also raise a host of questions, not the least of which is this: Can your employer require that you get vaccinated? The answer: Yes, in many cases, employment attorneys said.

Weeks before states expect to receive their first shipments of Covid-19 vaccines, conflicting messages from the federal government have obscured exactly how many doses may arrive. Some governors, including New York’s Andrew Cuomo and California’s Gavin Newsom, have made splashy announcements about how much of Pfizer Inc. and BioNTech SE’s vaccines they expect should the U.S. Food and Drug Administration authorize them this month. Other states can’t provide a solid answer given how quickly estimates change.

Forget one-time holiday deals. “We’re seeing a different transformation in the retail market and e-commerce is taking off in ways that are unbelievable,” said Sheldon Jacobson, a professor of computer science at the University of Illinois. That means you will need to do more research for the best price. “It’s prudent for people to sign up for a variety of retailers online and have emails come because they’ll tell you when their sales are,” Jacobson said. This year mindful gifts that focus on self-care or that can be used at home are topping holiday lists.

Recent announcements by Pfizer and BioNTech SE, Moderna, and AstraZeneca on their coronavirus vaccines have been promising. With so many companies racing to develop a vaccine, there are certain to be additional announcements forthcoming, ideally with comparable or even better efficacy data, less stringent cold-chain storage requirements, and even less adverse side effects. Although there are many more hurdles to traverse, establishing the efficacy of a vaccine in less than one year is nothing short of remarkable.